Paul A Marks

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Ronald Breslow, P. Marks, R. Breslow, 2007, Nature Biotechnology.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Marie Joseph, Masaharu Akiyama, T. Libermann, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Blasts from the past.

Paul A Insel, T. Stossel, A. Varki, 2004, The Journal of clinical investigation.

Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor

G. Perez, L. Ngo, P. Marks, 2006, Proceedings of the National Academy of Sciences.

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

Gordon K Smyth, Andrew J Holloway, Ricky W Johnstone, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Prospects: Histone deacetylase inhibitors

M. Dokmanovic, Paul A Marks, Milos Dokmanovic, 2005, Journal of cellular biochemistry.

Histone deacetylase inhibitors: from target to clinical trials

P. Marks, O. O’Connor, W. Kelly, 2002, Expert opinion on investigational drugs.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease

Leslie M Thompson, Cathryn M Lewis, C. Lewis, 2003, Proceedings of the National Academy of Sciences of the United States of America.